ASH 2022 Conference Coverage - A Focus on GVHD for Pharmacists

syringe pushed into medical vial stopper on black background

Itacitinib Plus Corticosteroids for Chronic GVHD

At the 64th ASH Annual Meeting and Exposition, researchers presented early findings from the dose-finding portion of GRAVITAS-309, a study on itacitinib combined with...
cyclophosphamide molecular formula

PTCy, Abatacept, and Tacrolimus for GVHD Prophylaxis

Haploidentical blood and marrow transplantation (BMT) has significantly increased the number of eligible hematopoietic stem cell donors; however, the outcomes of these transplants are...
Baricitinib vial with syringe in clean tray

Baricitinib Plus Standard GVHD Prophylaxis: Phase 1 Results

Researchers, led by Mark A. Schroeder, MD, conducted a single-arm, open-label phase 1 trial to evaluate the safety of baricitinib, a balanced Janus kinase...
doctor with patient in office explaining survey

The Lasting Impact of Surviving Severe aGVHD

Patients who recover from grade 3-4 acute graft-versus-host disease (aGVHD) after allogeneic hematopoietic cell transplantation (HCT) demonstrated greater risk for late comorbidities, higher rates...
space-filling model of ruxolitinib molecule

Impact of Ruxolitinib Initiation Timing

Studies suggest that between 35% and 60% of patients with acute graft-versus-host disease (aGVHD) become resistant to corticosteroids. Prolonged corticosteroid therapy also involves increased...
3d illustration of human gastrointestinal tract on dark blue background

Pilot Data on Fecal Microbiotherapy for Acute GI GVHD

In a presentation at the 64th ASH Annual Meeting and Exposition, researchers presented findings from a pilot study on the pooled allogeneic fecal microbiotherapy...
diagram of t-cell activation process

PRMT5 Identified as Potential GVHD Treatment Target

Previously, Katiri Snyder and colleagues determined that the enzyme protein arginine methyltransferase 5 (PRMT5) was upregulated in acute graft-versus-host disease (aGVHD) and that PRMT5...
corticosteroid bottle and syringe on pink background

Ruxolitinib With Corticosteroids in Pediatric GVHD

In a presentation at the 64th ASH Annual Meeting and Exposition, Franco Locatelli, MD, presented the first evidence reported in the phase 1/2 REACH4...
blue latex gloved-hand holding blood tube with separated plasma

Belumosudil Significantly Affects IST Serum Concentrations

Recently, the novel Rho-associated coiled-coil containing protein kinase 2 (ROCK2) inhibitor, belumosudil, was approved for the treatment of chronic graft-versus-host disease (GVHD) in patients...
Malignant bone marrow photomicrograph

Adding Itacitinib to Conventional GVHD Prophylaxis

In a recent study, researchers from the Hope National Medical Center in Duarte, California, evaluated the safety and efficacy of adding itacitinib to standard...

More From DocWire

Curated Journal reading List

Advertisement
Advertisement

Expert Interviews